This review discusses the evidence in support of the use of golimumab, its pharmacology including its mechanism of action, and efficacy and tolerability as demonstrated in pivotal clinical trials. It also provides commentary and recommendations from Associate Professor Paul Bird, a Rheumatologist in private practice and Conjoint A/Professor at the University of New South Wales.
Please login below to download this issue (PDF)